OR WAIT null SECS
© 2022 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2022 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Processing Equipment Trends
Data analytics, modular equipment, digital tools, and risk-based validation improve speed, flexibility, and quality.
Opportunities and developments in particle engineering are providing developers with the tools to advance drug candidates successfully.
Advancements in soft capsule technology can enable the development of soft capsule formulations.
Examining new approaches, novel technologies, and the structural evolution of the raw materials market.
Replacing a step in sample preparation with an automated approach improves both method precision and productivity.
Advancing OSD: Continuous Production Considerations and Dose-Level Authentication
November 30, 2022
AstraZeneca inked a deal worth up to $320 million to purchase Neogene Therapeutics, a biotech start-up focused on T-cell receptor therapies.
The agreement will see Immutep and Merck KGaA, Darmstadt, Germany jointly fund the INSIGHT-005 study.
Aptamer’s new 18,000 ft² facility will expand the company's capacity to deliver novel binders for bioprocessing, diagnostic, and drug development.
Etihad Cargo is one of the only airlines to hold IATA CEIV Pharma certification globally.
November 29, 2022
The decision to move forward in Phase III development stems from the threat of resistance to current malaria treatment growth.
November 28, 2022
High-cost-per-dose large molecules can make a big impact on cell and gene therapy supply chain management.
SPX-001, a respiratory drug candidate, will be submitted through a combined Clinical Trial and Ethics Committee application for further advancement in the clinical stages.
CSL’s Hemgenix (etranacogene dezaparvovec) will cost approximately $3.5 million, making it the most expensive single-use medicine in the United States.
Merck will purchase Imago BioSciences, a biotechnology company focused on bone marrow disorders, for approximately $1.35 billion.
The agreement aims to develop integrated technology for large-scale exosome production.